Raymond James analyst John Ransom lowered the firm’s price target on CVS Health (CVS) to $110 from $115 and keeps an Outperform rating on the shares. CVS Health’s Q4 results were in line with their preannouncement, 2023 guidance was maintained, and the company announced the acquisition of Oak Street Health (OSH), the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CVS:
- 3 Stocks to Buy Today, 2/10/2023, According to Top Analysts
- Oak Street Health downgraded to Hold from Buy at Jefferies
- CVS Health price target lowered to $110 from $118 at Barclays
- CVS Health Corp Earnings Report: Is it a Beat?
- Early notable gainers among liquid option names on February 8th
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue